Effect of chronic liver disease on clinical outcome in renal allograft recipients

Transplant Proc. 1997 Feb-Mar;29(1-2):787-90. doi: 10.1016/s0041-1345(96)00102-9.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antilymphocyte Serum / therapeutic use
  • Biopsy, Needle
  • Blood Transfusion
  • Female
  • Follow-Up Studies
  • Graft Rejection / epidemiology
  • Graft Rejection / therapy
  • Graft Survival*
  • Hepatitis B / epidemiology*
  • Hepatitis B / pathology
  • Hepatitis B Surface Antigens / blood
  • Hepatitis C / epidemiology*
  • Hepatitis C / pathology
  • Hepatitis C Antibodies / blood
  • Histocompatibility Testing
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation* / mortality
  • Kidney Transplantation* / physiology
  • Liver / pathology
  • Male
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Muromonab-CD3 / therapeutic use
  • Postoperative Complications*
  • Prevalence
  • Risk Factors
  • Survival Rate
  • Treatment Outcome

Substances

  • Antilymphocyte Serum
  • Hepatitis B Surface Antigens
  • Hepatitis C Antibodies
  • Immunosuppressive Agents
  • Muromonab-CD3
  • Methylprednisolone